Objective-Because platelets are anucleate cells having a limited life span, direct gene manipulation cannot in principle be used to investigate the involvement of a specific signal transduction pathway in platelet activation. In this study, we examined whether the expression of a short hairpin RNA (shRNA) sequence in hematopoietic stem cells is maintained during megakaryocyte differentiation, thus resulting in inhibition of targeted protein in platelets. Methods and Results-To identify platelets derived from transduced stem cells, we generated a lentiviral vector that simultaneously expresses the shRNA sequence driven by the U6 promoter and GFP under the control of the glycoprotein (GP) Ib␣ promoter. Transplantation of mouse bone marrow cells transduced with the vector facilitated specifically mark platelets derived from the transduced cells. Transplantation of cells transduced with shRNA sequence targeting integrin ␣IIb caused a significant reduction of integrin ␣IIb␤3 (␣IIb␤3) expression in GFP-positive platelets. It also inhibited ␣IIb␤3 activation assessed by the binding of JON/A, an antibody that recognizes activated ␣IIb␤3. Talin-1 silencing by the same method resulted in normal ␣IIb␤3 expression but deficient inside-out ␣IIb␤3 signaling. Conclusions-shRNA expression driven by the U6 promoter is preserved during megakaryopoiesis. This method facilitates functional analysis of targeted protein in platelet activation. (Arterioscler Thromb Vasc Biol.
P latelets are terminally-differentiated circulating anucleate cells whose adhesive and signaling functions are essential for normal hemostasis. Platelets are produced in the bone marrow from megakaryocytes as cytoplasmic fragments without genomic DNA. 1 Although platelets contain mRNA within their cytoplasm and can respond to physiological stimuli using biosynthetic processes regulated at the protein translation level, 2,3 application of direct genetic manipulation in platelets has not been reported. Alternatively, megakaryocyte lineage cells derived from embryonic or hematopoietic stem cells are amenable to genetic manipulation using gene transduction systems, enabling molecular studies of adhesion and signaling in megakaryocytes in a way not possible with platelets. 4, 5 Because platelets and their precursor megakaryocytes have a finite lifespan, hematopoietic stem cells are preferable targets for genetic transfer to establish long-term in vivo expression of the targeted protein in platelets. 6 When a retroviral vector containing the integrin ␤3 (␤3) gene driven by the integrin ␣IIb (␣IIb) promoter was transduced into CD34 ϩ cells from a Glanzmann thrombasthenia patient with defects in the ␤3 gene, integrin ␣IIb␤3 (␣IIb␤3) was detected after in vitro megakaryocyte differentiation. 7 We have previously shown that transduction of hematopoietic stem cells with lentiviral vector harboring the glycoprotein (GP) Ib␣ promoter enables specific and efficient expression of the targeted protein in platelets in vivo. 8 Further, the therapeutic expression of ␣IIb␤3 in ␤3-deficient mice using a lentivirus vector containing ␤3 complimentary DNA (cDNA) under the control of the ␣IIb promoter has been reported. 9 These data indicate that gene expression driven by a platelet-specific promoter using the transduction of hematopoietic stem cells with lentiviral vector can be applied to investigations of the involvement of specific proteins in platelet signaling pathways. However, there has been no evaluation of whether the knock-down of targeted proteins in hematopoietic stem cells using a short hairpin RNA (shRNA) sequence results in sufficient protein reduction in platelets. In this study, we examined whether shRNA expression driven by the RNA polymerase III promoter is sustained during megakaryopoiesis, and whether gene silencing with shRNAs is applicable to analyzing the functions of ␣IIb␤3 in in vivo platelets.
immunohistochemistry are described in detail in the supplemental materials, available online at http://atvb.ahajournals.org.
Results

Efficient GFP Expression in Platelets Using LentiLox Vector Harboring GPIb␣ Promoter In Vivo
We first substituted the CMV promoter of pLL3.7, a lentiviral gene transfer vector which simultaneously expresses shRNA and GFP (LentiLox-CMV), 10 with the platelet-specific GPIb␣ promoter (LentiLox-GPIb␣) (supplemental Figure I) . To compare strengths and the specificities of the CMV and GPIb␣ promoters and to assess GFP transduction using these lentiviral vectors in vivo, bone marrow cells transduced with LentiLox-CMV or LentiLox-GPIb␣ were transplanted into the recipient mice. When bone marrow cells transduced with LentiLox-CMV were transplanted, GFP expression was observed in 14% to 32% of CD45 ϩ cells and in 0.7 to 2.4% of platelets in peripheral blood (supplemental Figure II) . As described previously, 8 transduction with LentiLox-GPIb␣ resulted in efficient GFP gene marking in platelets (10% to 22%); however, only marginal GFP expression was observed in CD45 ϩ and red blood cells (supplemental Figure II) . These data suggested that the LentiLox-GPIb␣ system enables specific GFP marking of platelets derived from transduced hematopoietic stem cells.
Efficiency of Lentiviral shRNA for Silencing of Targeted Protein Expression
We next validated the effects of shRNA sequence expression driven by the U6 promoter in LentiLox on expression of the targeted protein. We selected the shRNA sequences for integrin ␣IIb (supplemental Figure IB) , so that it was easy to validate the expression and function of this protein using flow cytometry. We also chose talin-1 sequences as a test case for intracellular protein (supplemental Figure IB) ; because talin is responsible for ␤ integrin activation but its function in in vivo platelets has not been evaluated. Because a molecular defect affecting 1 of the 2 integrin-coding genes is sufficient to cause a concomitant deficit of both ␣IIb and ␤3, 11 we prepared the 2 expression plasmids containing cDNA of ␣IIb and ␤3 for the expression of ␣IIb␤3 complexes. To determine the efficiency of lentiviral shRNA for ␣⌱⌱b-A, the surface expression of ␣⌱⌱b␤3 in HEK293 cells was determined after cotransfection of the shRNA constructs with integrin ␣⌱⌱b and ␤3 expression plasmids. As shown in Figure 1A , ␣⌱⌱b␤3 expression on the cell surface was significantly inhibited by cotransfection with the shRNA constructs for ␣IIb. On the other hand, other shRNA sequences did not affect the surface expression of ␣⌱⌱b␤3 ( Figure 1A ). As well, shRNA sequences for talin-1 specifically inhibited ectopically-expressed talin in HEK293 cells ( Figure 1C ). Sequences for ␣IIb-A and talin did not influence the expressions of GPVI and vinculin ( Figure 1B and 1D). The degradation of mRNA by shRNA expression was confirmed by real-time quantitative RT-PCR (supplemental Figure III) . The construct expressing the shRNA sequence ␣⌱⌱b-A and talin-A caused a more powerful inhibition of the expressions of ␣IIb and talin, respectively ( Figure 1A and 1C) . To rule out the off-targeting effect caused by the high concentration of shRNA, we validated the specificity of these shRNA sequences by a lower concentration of plasmid vectors (0.2 g; data not shown). Hence, we selected the ␣⌱⌱b〈 and talin-A sequences for in vivo experiments.
Silencing of ␣IIb␤3 Expression In Vivo Platelets by Transplantation of Transduced Bone Marrow Cells With shRNA Lentiviral Vector
We next examined the effects of shRNA driven by the U6 promoter during megakaryopoiesis in vivo. The bone marrow cells transduced with LentiLox-GPIb containing the scramble sequence (LentiLox-scramble-GPIb␣) or ␣⌱⌱b〈 sequence (LentiLox-␣⌱⌱b〈-GPIb␣) were transplanted into recipient mice. After transplantation, GFP expression was observed in 15% to 20% of platelets in both transplanted groups (data not shown). It is of note that ␣IIb␤3 expression in GFP-positive platelets was significantly reduced in the recipient mice transplanted with cells transduced with LentiLox-␣⌱⌱b〈-GPIb␣ (Figure 2A and 2B) . As well, JON/A binding after ADP stimulation, which recognizes activated ␣⌱⌱b␤3, was reduced to a greater extent by the transduction with LentiLox␣⌱⌱b〈-GPIb␣ (Figure 2B and 2D) . The discrepancy in the results between ␣⌱⌱b␤3 expression and JON/A binding is thought to be partly the result of the expression of an incompetent ␣⌱⌱b␤3 complex that is recognized as antigen but does not act as functional receptor. Because ␣IIb is the most abundant protein in platelets, it is possible that mRNA degradation of ␣IIb by siRNA in platelets becomes incomplete. Under the same conditions, GPIb and GPVI expressions were not affected (data not shown). Additionally, P-selectin expression after platelet activation was hardly affected ( Figure 2C and 2D ). These data suggested that the expression of the shRNA sequence driven by the U6 promoter is maintained during megakaryopoiesis, and that this method can be applied to investigations of the involvement of specific proteins in platelet activation.
Silencing of Talin in Platelets Decreases ␣⌱⌱b␤3 Activation
We next examined whether talin-1 knockdown affects ␣⌱⌱b␤3 activation in in vivo platelets, using shRNA silencing. Although talin is believed to be involved in the final common step of integrin ␣⌱⌱b␤3 activation, 12 functional analysis in in vivo platelets has not been performed. When bone marrow cells transduced with LentiLox-scrambleGPIb␣ or LentiLox-talinA-GPIb␣ at an MOI of 30 were transplanted, we confirmed the inhibition of talin expression in platelets derived from the cells transduced with LentiLoxtalinA-GPIb␣ by intracellular flowcytometry ( Figure 3A ). In addition, talin reduction was also verified after sorting of GFP-positive platelets by immunoblotting ( Figure 3B ). On the other hand, the expressions of ␣⌱⌱b␤3, GPIb␣, and GPVI were not affected (data not shown). As shown in Figure 3C through 3E, in talin-deficient platelets identified as GFPpositive cells, ␣⌱⌱b␤3 activation after ADP or convulxin stimulation was significantly decreased. Furthermore, talindeficient platelet partly affected the expression of P-selectin after the platelet stimulation ( Figure 3D and 3E ). These data clarified that talin was involved not only in ␣⌱⌱b␤3-dependent platelet activation but also in the release reaction in actual platelets.
Finally, using a platelet adhesion assay we attempted to determine whether talin-deficient platelets influenced the spreading onto fibrinogen. Platelet adhesion to immobilized 
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fibrinogen by itself was not inhibited by the deficiency of talin (Figure 4 ). However, platelet spreading after stimulation with PMA was markedly suppressed (Figure 4 ), suggesting that talin is required for platelet spreading on fibrinogen.
Discussion
RNA interference using siRNAs to inhibit specific gene expression is a powerful and promising technology for both basic research and therapeutic intervention. 13, 14 A number of vector systems have been reported to mediate stable transduction and expression of shRNAs in mammalian cells. 13 Among them, lentiviral vectors have been demonstrated to have the ability to stably transduce nondividing cells such as stem cells through integration of the vector DNA into the genome. 10, 15 RNA polymerase III promoters, most commonly the H1 and U6 promoters, have been incorporated into the lentiviral vectors for stable expression of shRNAs. 13 The potential problem for functional genomics studies inherent in transfection with shRNA is variability in transfection efficiency. A solution to this problem is coexpression of reporter genes such as GFP, which facilitates the selection of transduced cells. To obtain efficient gene marking of platelets derived from transduced hematopoietic stem cells, we substituted the ubiquitous CMV promoter of LentiLox with the platelet-specific GPIb␣ promoter and showed that transplantation of bone marrow cells transduced with the vector enabled specific marking of platelets derived from transduced hematopoietic stem cells expressing shRNA sequence. Platelets are terminally-differentiated anucleate cells, and for this reason direct gene transfer and silencing using virus or plasmid vector have been thought to be impossible. Since the development of gene targeting technologies in embryonic stem cells, 16 the "gold standard" for the analysis of gene function in platelets has been the creation of knockout mice. A large number of knockout studies have shown aberrant platelet phenotypes. [17] [18] [19] [20] However, one of the major drawbacks of conventional knockouts is that if the gene product is essential in many tissues, then it is quite likely that the consequence of homozygosity for the mutated allele will be lethality. Several experimental strategies are used or have the potential to overcome the problem of lethality. First, improvements in the technological procedures have allowed for refined analyses of gene functions at specific developmental stages or in specific tissues, based on conditional knock-out strategies by means of Cre-lox-regulated recombination. 21 Another solution, which has been applied in a few cases, is to use hematopoietic cells from fetal liver of knockout embryos to reconstitute the hematopoietic system of lethally-irradiated wild-type animals. 22, 23 Despite these significant improvements, the creation of loss-of-function alleles in the mouse remains time-consuming and costly. Our demonstration that the expression of shRNAs driven by RNA polymerase III promoters can be used to functionally silence protein expression in platelets suggests that RNAi-based technologies might represent a convenient strategy for the study of platelet signal transduction. Our methods could in fact detect platelets derived from transduced stem cells as GFP-positive platelets, and so enable the examination of the involvement of target proteins in platelet signal transduction by flow cytometry and adhesion assay. However, GFP-positive platelets after the transplantation were limited by up to 20% in our protocols. Hence, platelet aggregation testing and the analysis of intracellular signaling pathways including tyrosine phosphorylation are not thought impossible. Higher transfection efficiencies would be required to demonstrate genuine effects and to be a valid alternative to making gene knockout mice.
Cellular control of integrin activation is essential for normal development because it controls cell adhesion, migration, and assembly of the extracellular matrix. 24, 25 Platelets express members of the ␤1 subfamily (␣v␤1, ␣2␤1, and ␣6␤1) that support platelet adhesion to the extracellular matrix proteins including collagen and laminins, as well as expressing members of the ␤3 subfamily (␣v␤3 and ␣IIb␤3). 24 Among them, ␣IIb␤3, a receptor for fibrinogen, von Willebrand factor (VWF), fibronectin, and vitronectin is an essential requirement for platelet aggregation. Integrin activation can be controlled by signaling pathways that are thought to act by regulating specific interactions between cytoplasmic proteins and the integrin-or ␤-subunit-cytoplasmic tail. 25, 26 Although many types of proteins interacting with integrin cytoplasmic tails have been reported to be involved in platelet aggregation, 12,27-31 functional analysis of in vivo platelets has not been reported; embryos lacking these proteins, including talin, vinculin, FAK, and Cas do not normally grow in the uterus. [32] [33] [34] [35] Talin is a major cytoskeletal protein that colocalizes with activated integrins and binds to integrin ␤ cytoplasmic domains; with the overexpression of the N-terminal region of talin results in activation of integrins. 14, 28, 36 Additionally, binding of talin to integrin ␤ tails has been shown to be a common final step in integrin activation. 12 In this study, using a method involving RNA interference, we clearly demonstrated that talin is involved in ␣IIb␤3-dependent platelet activation in in vivo platelets. Furthermore, talin might partly participate in the ␣-granule release reaction. These results confirmed that this strategy could be useful as a convenient and powerful method to investigate the role of specific proteins in platelet activation in vivo.
